Outlook on the Pharmaceutical CDMO North American Market to 2030 – Impact Analysis of COVID-19

This article was originally published on this site

DUBLIN, Jan. 13, 2021 /PRNewswire/ — The “North America Pharmaceutical Contract Development and Manufacturing Organization (CDMO) Market 2020-2030 by Category, Service Type (CMO, CRO), Therapeutic Application, End User, and Country” report has been added to ResearchAndMarkets.com’s offering.

The North American pharmaceutical CDMO market is expected to grow by 6.0% annually in the forecast period and reach $101.1 billion by 2030 driven by increasing demand for biological therapies and specialty medicines, rising demand for cost control in drug development, and rising healthcare expenditures.

Highlighted with 37 tables and 50 figures, this report is based on comprehensive research of the entire North America pharmaceutical CDMO market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies of the period 2015-2019 and provides a forecast from 2020 till 2030 with 2019 as the base year.

In-depth qualitative analyses include identification and investigation of the following aspects:

  • Market Structure
  • Growth Drivers
  • Restraints and Challenges
  • Emerging Product Trends & Market Opportunities
  • Porter’s Fiver Forces

The trend and outlook of North America market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify North America pharmaceutical CDMO market in every aspect of the classification from perspectives of Category, Service Type, Therapeutic Application, End User, and Country.

Based on Category, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

  • Pharmaceutical Industry
  • Biopharmaceutical Industry

Based on Service Type, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Pharmaceutical Contract Manufacturing Organization (CMO)

  • Active Pharmaceutical Ingredients (API) (further split into Branded API Manufacturing and Generic API Manufacturing)
  • Finished Dosage Formulations (FDF) (further segmented into Solid Dosage, Oral Liquids, Parenteral/Injectables, Other FDFs)
  • Secondary Packaging

Pharmaceutical Contract Research Organization (CRO)

  • CRO for Pre-clinical Development
  • CRO for Phase I Trials
  • CRO for Phase II Trials
  • CRO for Phase III Trials
  • CRO for Phase IV Trials
  • Laboratory Services
  • Consulting Services
  • Data Management Services

Based on Therapeutic Application, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

  • Infectious Diseases
  • Oncology
  • Metabolic Disorders
  • Cardiovascular Disorders
  • Central Nervous System
  • Pulmonary Disorders
  • Gastrointestinal Disorders
  • Other Therapeutic Applications

Based on End User, the North America market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

  • Pharmaceutical & Biopharmaceutical Companies
  • Medical Device Companies
  • Academic Institutes

Geographically, the following national/local markets are fully investigated:

  • U.S.
  • Canada
  • Mexico

For each key country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of key national markets by Category, Service Type, and Therapeutic Application over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in North America pharmaceutical CDMO market are assayed quantitatively and qualitatively through a Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Topics Covered:

1 Introduction
1.1 Industry Definition and Research Scope
1.1.1 Industry Definition
1.1.2 Research Scope
1.2 Research Methodology
1.2.1 Overview of Market Research Methodology
1.2.2 Market Assumption
1.2.3 Secondary Data
1.2.4 Primary Data
1.2.5 Data Filtration and Model Design
1.2.6 Market Size/Share Estimation
1.2.7 Research Limitations
1.3 Executive Summary

2 Market Overview and Dynamics
2.1 Market Size and Forecast
2.1.1 Impact of COVID-19 on World Economy
2.1.2 Impact of COVID-19 on the Market
2.2 Major Growth Drivers
2.3 Market Restraints and Challenges
2.4 Emerging Opportunities and Market Trends
2.5 Porter’s Fiver Forces Analysis

3 Segmentation of North America Market by Category
3.1 Market Overview by Category
3.2 Pharmaceutical Industry
3.3 Biopharmaceutical Industry

4 Segmentation of North America Market by Service Type
4.1 Market Overview by Service Type
4.2 Pharmaceutical Contract Manufacturing Organization (CMO)
4.2.1 Active Pharmaceutical Ingredients (API)
4.2.2 Finished Dosage Formulations (FDF)
4.2.3 Secondary Packaging
4.3 Pharmaceutical Contract Research Organization (CRO)
4.3.1 CRO for Pre-clinical Development
4.3.2 CRO for Phase I Trials
4.3.3 CRO for Phase II Trials
4.3.4 CRO for Phase III Trials
4.3.5 CRO for Phase IV Trials
4.3.6 Laboratory Services
4.3.7 Consulting Services
4.3.8 Data Management Services

5 Segmentation of North America Market by Therapeutic Application
5.1 Market Overview by Therapeutic Application
5.2 Infectious Diseases
5.3 Oncology
5.4 Metabolic Disorders
5.5 Cardiovascular Disorders
5.6 Central Nervous System
5.7 Pulmonary Disorders
5.8 Gastrointestinal Disorders
5.9 Other Therapeutic Applications

6 Segmentation of North America Market by End User
6.1 Market Overview by End User
6.2 Pharmaceutical & Biopharmaceutical Companies
6.3 Medical Device Companies
6.4 Academic Institutes

7 North America Market 2019-2030 by Country
7.1 Overview of North America Market
7.2 U.S.
7.3 Canada
7.4 Mexico

8 Competitive Landscape
8.1 Overview of Key Vendors
8.2 New Product Launch, Partnership, Investment, and M&A
8.3 Company Profiles
8.3.1 Company Profiles of CMO

  • Aenova Group
  • Baxter BioPharma Solutions
  • Boehringer Ingelheim
  • Catalent Inc.
  • Famar S.A.
  • Hospira, Inc.
  • Jubilant Life Sciences Ltd.
  • Lonza Group
  • Patheon Inc.
  • Pfizer CentreSource
  • Recipharm AB
  • Vetter Pharma International GmbH

8.3.2 Company Profiles of CRO

  • Charles River Laboratories
  • CMIC Co. Ltd
  • Covance Inc.
  • Hangzhou Tigermed Consulting Co Ltd
  • ICON Plc
  • IQVIA Holdings Inc.
  • LSK North America Pharma Service Co Ltd
  • Novotech Pty Ltd
  • PAREXEL International Corporation
  • Pharmaceutical Product Development LLC (PPD)
  • PRA Health Sciences Inc.
  • Quanticate Ltd
  • Samsung Bioepis Co. Ltd
  • SGS SA (SGS Life Sciences)
  • Syneos Health Inc.
  • WuXi AppTec Inc.

9 Investing in North America Market: Risk Assessment and Management
9.1 Risk Evaluation of North America Market
9.2 Critical Success Factors (CSFs)

For more information about this report visit https://www.researchandmarkets.com/r/xrfswl

Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research.

Media Contact:

Research and Markets
Laura Wood, Senior Manager

For E.S.T Office Hours Call +1-917-300-0470
For U.S./CAN Toll Free Call +1-800-526-8630
For GMT Office Hours Call +353-1-416-8900

U.S. Fax: 646-607-1907
Fax (outside U.S.): +353-1-481-1716

View original content:https://www.prnewswire.com/news-releases/outlook-on-the-pharmaceutical-cdmo-north-american-market-to-2030—impact-analysis-of-covid-19-301207680.html

SOURCE Research and Markets